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Abstract
The prevalence of obstructive sleep apnea-hypopnea syndrome (OSAHS) ranges from 4 to 7% in men and from 2 to 5% in wo-
men. Its deleterious consequences such as traffic accidents, cardiovascular complications increasing morbidity and mortality, 
make it a major health problem. Apart from obesity (a major risk factor for OSAHS), hypothyroid patients are prone to reveal this 
phenotype. Although hypothyroidism seems an acknowledged risk factor for OSAHS, some authors report the lack of clinically 
relevant association. The argument partly depends on the increased prevalence of hypothyroidism in OSAHS patients, but the 
epidemiological data is limited and somehow inconsistent; even less is known about sub-clinical hypothyroidism in OSAHS 
patients. Even if frequency of overt and sub-clinical hypothyroidism in OSAHS patients is comparable to the general population, 
screening for it seems beneficial, as hormone replacement therapy may improve sleep disordered breathing. Unfortunately, this 
favorable outcome was found only in a few studies with limited number of patients with hypothyroidism. Yet, despite the lack of 
international guidelines and no large multicentre studies on the topic available, we think that TSH screening might prove beneficial 
in vast majority of OSAHS patients.
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Obstructive sleep apnea-hypopnea syndrome
Obstructive sleep apnea — hypopnea syn-
drome (OSAHS) is a chronic condition, charac-
terized by recurrent pauses in breathing during 
sleep. In consequence, they lead to sleep fragmen-
tation and intermittent hypoxemia. Decreased 
quality of sleep leads to excessive day time sleep-
iness, cognitive dysfunction and impaired work 
performance [1]. OSAHS contributes to systemic 
hypertension [2], cardiovascular diseases [3] and 
abnormalities in glucose metabolism [4]. The 
reported prevalence of OSAHS in adult popula-
tion ranges from 4 to 7% in men, and from 2 to 
5% in women [1, 5]; with some subgroups of the 
population bearing higher risk [1]. It is a serious 
health problem considering high prevalence and 
its deleterious consequences, e.g. traffic accidents 
or all causes related morbidity and mortality 
[6−8]. Polysomnography is an acknowledged gold 
standard in OSAHS diagnostics.
Clinical and sub-clinical hypothyroidism
Primary hypothyroidism is a condition, in 
which thyroxin levels in blood are reduced and 
are accompanied by increased levels of TSH as an 
effect of disruption of negative feedback mecha-
nism. Thus, hypothyroidism is diagnosed when 
concentration of serum TSH exceeds 4.5 mIU/L 
and free T4 (FT4) concentration is below the ref-
erence range: 0.8−2.0 ng/dL (10.3−25.7 pmol/L). 
The reported prevalence of overt hypothyroidism 
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lies within wide range — from 0.3% even up to 
9.2%. The condition presents more often among 
women [9].
The term sub-clinical hypothyroidism has 
been coined for a  condition defined as serum 
TSH concentration above the upper limit of the 
reference range (4.5 mIU/L) with serum free T4 
(FT4) concentration within normal range (usually 
low normal) [10]. The prevalence of sub-clinical 
hypothyroidism is higher than the overt one and 
ranges between 3% and 18% in the adult popu-
lation [11].
There is a substantial risk of 2 to 6% yearly 
for the progression of sub-clinical hypothyroid-
ism to the overt one, with females being at higher 
risk. Other factors that may predispose to the 
progression include: higher levels of TSH and 
presence of antithyroid peroxidase antibodies. 
On the other hand, TSH levels normalize sponta-
neously in 15 to 65% of cases with elevated TSH 
found in a single blood sample (follow-up periods 
lasting 1 up to 6 years). Conversely to progression 
to overt hypothyroidism, a spontaneous recovery 
is more likely with individual TSH levels < 10 
mIU/l [10].
As numerous studies have shown, there are 
several risk factors for overt and sub-clinical 
hypothyroidism. These include gender, with 
women being more vulnerable than men [12, 13]. 
Another factor that may influence the level of 
serum thyrotropin is age — up to 18% of elderly 
suffer from this condition [11]. When these two 
factors overlap the prevalence of hypothyroidism 
among women over 60 years old may reach up 
to 24% [14]. Interestingly, populations that are 
sufficient in iodine are more prone to sub-clinical 
hypothyroidism [11]. Continuing, some studies 
suggest that in areas, where diet is deficient in 
iodine, serum TSH levels greater than 5 mlU/L 
are rare (1.5% among women over 60 years old) 
[15]. Other studies point to the same factors as de-
terminants of higher risk for sub-clinical thyroid 
disease including pregnant women and women 
older than 60 years [10].
Association of OSAHS  
and hypothyroidism
There is a great variance in reported prev-
alence of hypothyroidism among patients with 
OSAHS. Namely, it has ranged from 2% to 11% 
[16, 17].  OSAHS and hypothyroidism have similar 
symptomatology, which creates a significant risk 
for misdiagnosis. Moreover, hypothyroidism is 
a risk factor for OSAHS and one of a few causes 
thereof amenable to treatment. In effect, a hypo-
thyroid patient with secondary apneas may be 
misdiagnosed with primary OSAHS. Symptoms 
and signs common in both conditions include: 
obesity, fatigue, decreased libido, depressed 
mood, impaired concentration, snoring and 
witnessed apneas. The overlap in clinical pre-
sentation, creates a significant risk for OSAHS 
diagnosis among patients referred to sleep clinic 
who, actually, have undiagnosed hypothyroidism 
[17, 18].
Numerous papers address the relationship 
between OSAHS and hypothyroidism. Although 
hypothyroidism is an acknowledged risk factor for 
OSAHS, some controversy lingers, mainly due to 
studies that report the lack of clinically relevant 
association [16]. Moreover data on association 
between OSAHS and sub-clinical hypothyroidism 
are insufficient. In this case the differentiation 
may be even harder as individuals with sub-clini-
cal hypothyroidism are often pauci-symptomatic, 
and clinical presentation can include non-spe-
cific complaints and symptoms, partly similar 
to those seen in overt hypothyroidism, such as 
fatigue, weakness, weight gain, cold intolerance, 
and constipation [19]. Therefore, the opinions 
on necessity for clinical and sub-clinical hypo-
thyroidism screening in sleep apnea patients are 
divided into for and against positions.
Skjodt et al. [17] performed polisomnography 
and biochemical screening towards hypothyroid-
ism in 200 patients. Out of 124 patients, who were 
diagnosed with OSAHS (69%), only 3 were also 
discovered to have previously undiagnosed hypo-
thyroidism. These patients, were not included in 
the group treated with CPAP for the primary sleep 
apnea. Instead, they were treated with thyroxin 
therapy alone for their primary medical problem, 
which resulted in resolving sleep apnea — from 
ex-juvantibus inference a  secondary one. The 
authors concluded that biochemical screening 
for hypothyroidism is required to prevent inad-
vertent misdiagnosis of hypothyroid sleep-dis-
ordered breathing as primary sleep apnea [17]. 
Nevertheless, this study is a case series report 
and the conclusions drawn should be viewed 
with caution.
Rosen D. in his study presents a case of 5-year 
old child with Down Syndrome diagnosed with 
mild to moderate OSAHS. Subsequently to this 
diagnosis, biochemical screening for hypothy-
roidism was performed. Result showed that the 
child was suffering from severe hypothyroid-
ism, which caused secondary sleep apnea. After 
3 months of treatment with Levothyroxine res-
olution OSAHS was observed. The researcher 
Pneumonologia i Alergologia Polska 2016, vol. 84, no. 5, pages 302–306 
304
used this study to make a  point that routine 
thyroid function screening is not recommended. 
However, if a patient belongs to a high risk group 
of hypothyroidism it is important to pursue this 
diagnosis, as its treatment may bring partial or 
full resolution of OSAHS [20]. 
Similar investigations were carried out by 
Bahammam et al. in order to assess the concur-
rence of OSAHS and hypothyroidism. Moreover, 
in this study differentiation into clinical and 
sub-clinical hypothyroidism was introduced. 
Overall, among 254 patients, who were diagnosed 
with OSAHS, only 1 was newly diagnosed with 
overt hypothyroidism, but 26 had been previous-
ly diagnosed and were on thyroxin replacement 
therapy. Whereas, sub-clinical hypothyroidism, 
was diagnosed in 27 (10%) OSAHS patients. None 
of these patients had typical symptoms or signs of 
hypothyroidism apart from daytime fatigue and 
snoring. The prevalence of sub-clinical hypothy-
roidism was 13.7% and 7.7% in female and male 
OSAHS patients, respectively. Authors suggested 
that the prevalence of newly diagnosed cases 
of clinical hypothyroidism in OSAHS patients 
was too low to justify routine screening, unless 
hypothyroidism was suspected on the basis of 
symptoms or signs [12]. Although sub-clinical 
hypothyroidism was relatively common in this 
population, it is arguable whether this necessi-
tate routine screening, as the clinical relevance 
thereof is not yet clarified.
Another study, whose findings support 
screening for sub-clinical and clinical hypothy-
roidism was conducted by Ozcan et al. It includ-
ed 203 patients with mild to severe OSAHS. On 
evaluation of the thyroid function, 11% (n = 22) 
of the patients were found to have sub-clinical 
hypothyroidism and 2% (n = 4) overt hypothy-
roidism. There was no significant correlation be-
tween thyroid functions and severity of OSAHS, 
but due to the low number of cases the study 
was probably underpowered. Nevertheless, the 
researchers suggested that evaluation of the thy-
roid functions was warranted in patients with 
OSAHS which seems not well supported by the 
results of this study [21]. 
In a study by Mete et al. [22] a group of 150 
patients diagnosed with OSAHS and 32 control 
subjects were submitted to functional and ultra-
sonographic examination of thyroid gland. The 
authors did not find any difference in the prev-
alence of hypothyroidism, numbers of nodules, 
and parenchyma heterogeneity determined by ul-
trasound, between OSAHS patients and controls. 
Akin to the previous one, this study seems also 
underpowered due to the low number of cases 
per study group, especially unbalanced number 
of controls.
Bozkurt et al. [23] conducted a  study, on 
the prevalence of Hashimoto’s thyroiditis (HT), 
the most prevalent cause of hypothyroidism in 
populations with adequate iodine supply, in 245 
euthyroid individuals, who were suspected of 
having OSAHS. Diagnosis of HT was based on 
thyroid ultrasound and serum anti-thyroglobulin 
(anti-TG) and anti-thyroid peroxidase (anti-TPO) 
antibodies. HT was diagnosed in 32% of con-
trols and in 47% of all OSAHS patients. Severe 
OSAHS patients had higher HT frequency (52%) 
compared to other groups, while in a group of 
severe female OSAHS patients it was the highest 
(73%). The study showed that OSAHS patients 
presented higher HT prevalence, which correlated 
with the severity of OSAHS, and the association 
was stronger among women. Authors of the study 
pointed out that screening for thyroid disorders, 
not only for hypothyroidism but also for auto-im-
mune thyroid diseases in OSAHS patients may be 
of benefit for early diagnosis of a thyroid failure. 
What is more, they suggested that OSAHS may 
be a pathogenic factor for thyroid auto-immunity 
[23]. However, this statement is controversial and 
should be treated merely as a hypothesis and not 
a conclusion supported by results of the study.
Putative mechanisms of the association 
between OSAHS and hypothyroidism
There are several mechanisms that may play 
a  role in association of OSAHS and hypothy-
roidism. The proposed mechanisms for the rela-
tionship between OSAHS and hypothyroidism 
include the deposition of mucoproteins in the 
upper airway causing upper airway obstruction, 
disturbances of the regulatory control of pharyn-
geal dilator muscles due to neuropathy, and the 
possibility of respiratory center depression [24].
Individuals with sub-clinical hypothyroid-
ism suffer more often from weakness and my-
algia, and reduced muscle strength has been 
shown in these individuals, which may result in 
insufficient strength of skeletal muscles that are 
essential to regular ventilation or upper airways 
patency [25, 26]. Moreover, large goiters present 
in some patients with hypothyroidism alone can 
cause pharynx occlusion and thus OSAHS [27].
Implications for treatment
CPAP (continuous positive airway pressure) 
is a  standard treatment for OSAHS. However, 
in case of secondary OSAHS in the course of 
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hypothyroidism this may hardly revert apneas 
and hypopneas by securing upper airways pa-
tency, but not affecting the underlying pathology. 
Therefore, treating sleep disordered breathing 
with CPAP does not solve the problem of prima-
ry hypothyroidism. Conversely, in many cases, 
replacement therapy with thyroxin does not 
always prove enough to resolve sleep disordered 
breathing in patients with hypothyroidism. The 
clear recommendations on the treatment options, 
i.e. thyroxin alone or in combination with CPAP 
cannot be given as the data from clinical studies 
are limited. Skjodt et al. reported that 3 patients 
suffering from secondary sleep apnea were suc-
cessfully treated with thyroxin therapy alone 
with simultaneous resolution of sleep-disordered 
breathing, nocturnal hypoxia, and thyroid defi-
ciency [17]. Contrary, Mickelson et al. found that 
thyroid replacement therapy resulted in little or 
no improvement in sleep disordered breathing 
in 4 patients with clinical hypothyroidism [28]. 
Hence, introduction of thyroxin replacement 
therapy should be considered as a viable choice 
of treatment for OSAHS putatively secondary 
to hypothyroidism. However, it is advised that 
follow up in regard to sleep disordered breathing 
in patient undergoing such a treatment ought be 
performed. If OSAHS symptoms or better, objec-
tively monitored apneas don’t disappear following 
a few months of hormone therapy, CPAP should 
be introduced as a next step. However, one has to 
bear in mind that these conclusions were based 
on studies being effectively case reports or case 
series due to the low number of cases and thus 
may be severely biased and not applicable to the 
general population.
When it comes to sub-clinical hypothyroid-
ism most experts and societies suggest treatment 
of sub-clinical hypothyroidism if TSH levels are 
>10 mIU/l based on the available evidence, while 
taking into consideration other risk factors such 
as the presence of goiter, anti-thyroid antibodies, 
presence of cardiovascular risk or continuing 
clinical symptoms [10]. However, it is important 
to initiate treatment only after three to six months 
of follow-up given the high rate of spontaneous 
normalization of elevated TSH levels. It is mostly 
due to that fact that risks of treatment have been 
mainly associated with overtreatment, which is 
reported in 14% to 21% of sub-clinically hypothy-
roid individuals on thyroxin replacement therapy 
[11]. Whether the treatment of sub-clinical hypo-
thyroidism can influence concurrent OSAHS is 
dubious, since there is no reliable data supporting 
more frequent occurrence of sub-clinical hypo-
thyroidism in apneic patients, not to mention data 
in favor of sub-clinical hypothyroidism as a risk 
factor for OSAHS. Therefore, it seems preferable 
for patients with OSAHS and sub-clinical hypo-
thyroidism to focus on symptomatic treatment of 
apneas with CPAP and follow-up of TSH levels.
Conclusions
As there exists an overlap in clinical presen-
tation of primary OSAHS and hypothyroidism, 
it is currently discussed whether screening for 
hypothyroidism is needed. Available data from 
literature does not offer definite recommendation 
in favor of the routine screening.
Routine screening for thyroid disorders may 
prevent misdiagnosis and allows physicians to 
find primary condition and start hormone re-
placement therapy, inhibiting the progression of 
the primary disorder. In a few cases treatment 
of hypothyroidism as a primary condition re-
sulted in significant improvement of coexisting 
OSAHS. On the other hand, several authors point 
out the lack of substantial evidence for higher 
prevalence of hypothyroidism among patients 
suffering from OSAHS. Hence, they argue, there 
is no reason for the routine screening in this 
group of patients.
However, there is plausible middle ground 
between these opposite stances. It is reasonable 
to advise routine screening tests for thyroid dis-
orders in patients that belong to a high risk group 
(i.e. older women) or are overtly symptomatic. 
Moreover, an argument in favor of screening for 
thyroid disorders is an early diagnosis, which can 
prevent long term metabolic consequences and 
potentially deleterious exacerbation of the con-
dition. Also, although the prevalence of overt or 
sub-clinical hypothyroidism in OSAHS patients 
may not be increased, finding a subgroup of pa-
tients feasible for causal treatment may be a pro 
argument for the routine screening [17]. For prac-
ticing physicians it seems important to remember 
that hypothyroidism may be a reversible cause of 
OSAHS and that OSAHS may be a risk factor for 
hypothyroidism, though it is only an unproven 
hypothesis [27]. Yet, despite the lack of interna-
tional guidelines and no large multicentre studies 
on the topic, we think that TSH screening might 
prove beneficial in majority of OSAHS patients, 
with the caveat that cost-effectiveness  of such 
recommendation has not been addressed so far. 
This conclusion might be of value, regardless the 
existence of a causal association or just a concur-
rence of OSAHS and hypothyroidism. 
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This review is based on a limited number of 
studies with limited number of patients. There-
fore, the conclusions drawn should be considered 
as preliminary. Long-term, large group follow-up 
studies are needed to establish the possible signif-
icance of routine evaluation of OSAHS patients 
for thyroid diseases.
Conclusions
1. Limited and somewhat contrary data on the 
prevalence of hypothyroidism in OSAHS po-
pulation prevent drawing clear conclusions 
on existing association.
2. Hypothyroid patients are prone to reveal 
OSAHS phenotype but probably early dia-
gnosis and effective thyroxin treatment pre-
vent the overrepresentation of these patients 
in OSAHS patients.
3. Screening for hypothyroidism in OSAHS 
patients can potentially be rewarding as tre-
atment of hypothyroidism may ameliorate 
secondary OSAHS.
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